These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 15332494)

  • 1. FK506 as effective adjunct to L-dopa in reserpine-induced catalepsy in rats.
    Singh A; Naidu PS; Kulkarni SK
    Indian J Exp Biol; 2003 Nov; 41(11):1264-8. PubMed ID: 15332494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quercetin potentiates L-Dopa reversal of drug-induced catalepsy in rats: possible COMT/MAO inhibition.
    Singh A; Naidu PS; Kulkarni SK
    Pharmacology; 2003 Jun; 68(2):81-8. PubMed ID: 12711835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by L-DOPA.
    Alam M; Mayerhofer A; Schmidt WJ
    Behav Brain Res; 2004 May; 151(1-2):117-24. PubMed ID: 15084427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease.
    Segovia G; Mora F; Crossman AR; Brotchie JM
    Mov Disord; 2003 Feb; 18(2):138-49. PubMed ID: 12539206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitecapone and selegiline as effective adjuncts to L-DOPA in reserpine-induced catatonia in mice.
    Singh A; Kulkarni SK
    Methods Find Exp Clin Pharmacol; 2002; 24(1):23-9. PubMed ID: 11980384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
    Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
    Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
    Dekundy A; Pietraszek M; Schaefer D; Cenci MA; Danysz W
    Brain Res Bull; 2006 Apr; 69(3):318-26. PubMed ID: 16564428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic effect of SCH 58261, an adenosine A2A receptor antagonist, and L-DOPA on the reserpine-induced muscle rigidity in rats.
    Wardas J
    Pol J Pharmacol; 2003; 55(2):155-64. PubMed ID: 12926542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of reserpine-induced catalepsy by selective D1 and D2 dopamine agonists.
    Hubbard CA; Trugman JM
    Mov Disord; 1993 Oct; 8(4):473-8. PubMed ID: 7901761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
    Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
    Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of WA-335, a factor which blocks serotonin receptors, on neuroleptic-induced catalepsy.
    Maj J; Sowińska H; Baran L
    Arch Immunol Ther Exp (Warsz); 1976; 24(2):197-203. PubMed ID: 945050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Facilitation of the effects of L-DOPA by alpha-methyldopa].
    Uspenskiĭ AE; Korobov NV
    Biull Eksp Biol Med; 1976 Mar; 81(3):314-6. PubMed ID: 986203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Actions at sites other than D(3) receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted rats.
    Visanji NP; Millan MJ; Brotchie JM
    Exp Neurol; 2006 Nov; 202(1):85-92. PubMed ID: 16814282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of antidepressants with antiparkinsonian agents in rats.
    Zebrowska-Lupina I; Porowska A; Pietrasiewicz T
    Pol J Pharmacol Pharm; 1985; 37(6):865-74. PubMed ID: 3832020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.
    Rose S; Jackson MJ; Smith LA; Stockwell K; Johnson L; Carminati P; Jenner P
    Eur J Pharmacol; 2006 Sep; 546(1-3):82-7. PubMed ID: 16925991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonism of haloperidol-induced swim impairment in L-dopa and caffeine treated mice: a pre-clinical model to study Parkinson's disease.
    Luthra PM; Barodia SK; Raghubir R
    J Neurosci Methods; 2009 Apr; 178(2):284-90. PubMed ID: 19146880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy.
    Eskow KL; Gupta V; Alam S; Park JY; Bishop C
    Pharmacol Biochem Behav; 2007; 87(3):306-14. PubMed ID: 17553556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions.
    Kääriäinen TM; García-Horsman JA; Piltonen M; Huotari M; Männistö PT
    Basic Clin Pharmacol Toxicol; 2008 Mar; 102(3):300-7. PubMed ID: 17973898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced cortical dopamine output and antipsychotic-like effect of raclopride with adjunctive low-dose L-dopa.
    Eltayb A; Wadenberg ML; Svensson TH
    Biol Psychiatry; 2005 Aug; 58(4):337-43. PubMed ID: 16102547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.